95 related articles for article (PubMed ID: 37697)
1. Therapeutical significance of clopimozide in the treatment of chronic psychotic patients.
De Cuyper HJ; Van Praag HM; Mulder WR
Acta Psychiatr Scand; 1979 May; 59(5):561-74. PubMed ID: 37697
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of chronic psychoses with oral clopimozide].
Knapen J; Bollen J; Brugmanns J; Rombaut N
Acta Psychiatr Belg; 1976; 76(4):644-57. PubMed ID: 798469
[TBL] [Abstract][Full Text] [Related]
3. [Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double blind research].
Bures E; Pöldinger W
Int Pharmacopsychiatry; 1978; 13 Suppl 1():45-52. PubMed ID: 35479
[No Abstract] [Full Text] [Related]
4. [Open studies in comparison to controlled studies in testing of neuroleptics].
Pajonk FG; Holzbach R; Naber D
Fortschr Neurol Psychiatr; 2000 Jul; 68(7):313-20. PubMed ID: 10945157
[TBL] [Abstract][Full Text] [Related]
5. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.
De Deyn PP; Carrasco MM; Deberdt W; Jeandel C; Hay DP; Feldman PD; Young CA; Lehman DL; Breier A
Int J Geriatr Psychiatry; 2004 Feb; 19(2):115-26. PubMed ID: 14758577
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic efficacy of fluperlapine. An open multicenter trial.
Woggon B; Angst J; Bartels M; Heinrich K; Hippius H; Koukkou M; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pöldinger W
Neuropsychobiology; 1984; 11(2):116-20. PubMed ID: 6148712
[TBL] [Abstract][Full Text] [Related]
8. Double-blind- evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients.
Malfroid M; Hens L; Roosen P; Dom R
Acta Psychiatr Belg; 1978; 78(1):147-54. PubMed ID: 347877
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
[TBL] [Abstract][Full Text] [Related]
10. The behavioral toxicity of bromocriptine in patients with psychiatric illness.
Perovich RM; Lieberman JA; Fleischhacker WW; Alvir J
J Clin Psychopharmacol; 1989 Dec; 9(6):417-22. PubMed ID: 2574194
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration.
De Cuyper H; Bollen J; van Praag HM; Verstraeten D
Br J Psychiatry; 1986 May; 148():560-6. PubMed ID: 2877701
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
13. Indication of an antipsychotic action of the opiate antagonist naloxone.
Emrich HM; Cording C; Pirée S; Kölling A; von Zerssen D; Herz A
Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):265-70. PubMed ID: 30101
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.
Cummings JL; Street J; Masterman D; Clark WS
Dement Geriatr Cogn Disord; 2002; 13(2):67-73. PubMed ID: 11844887
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
16. [New "atypical" neuroleptics -- the emperor's new clothes?].
Dose M
Psychiatr Prax; 2003 Jan; 30(1):1-3. PubMed ID: 12524575
[No Abstract] [Full Text] [Related]
17. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
18. Assessment of anti-psychotic drugs.
Mackay AV
Br J Clin Pharmacol; 1981 Mar; 11(3):225-36. PubMed ID: 6111332
[No Abstract] [Full Text] [Related]
19. Clinical experiments with the new oral long-acting neuroleptic clopimozide (R 29 764).
Floru L; Tegeler J
Arzneimittelforschung; 1978; 28(2):341-4. PubMed ID: 25071
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.
Canuso CM; Lindenmayer JP; Kosik-Gonzalez C; Turkoz I; Carothers J; Bossie CA; Schooler NR
J Clin Psychiatry; 2010 May; 71(5):587-98. PubMed ID: 20492853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
